XIST and cancer: Based on these results, we concluded that XIST might serve as a prognostic biomarker in human cancers of gastric cancer, hepatocellular carcinoma, nasopharyngeal carcinoma, pancreatic cancer, osteosarcoma, esophageal squamous cell carcinoma and cervical squamous cell carcinoma.